Bio-Path Investor Relations Material

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company that operates in the United States. The Company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Bio-Path Holdings, Inc. was founded in 2007 and is headquartered in Bellaire, Texas.